Non-profit organisation International Partnership for Microbicides (IPM) has initiated the Phase I MTN-030/IPM 041 clinical trial of its three-month vaginal ring developed to prevent HIV and unintended pregnancy in women.

The ring uses technology similar to the dapivirine-only ring and is designed to slowly and simultaneously release the antiretroviral drug dapivirine, as well as the contraceptive hormone levonorgestrel.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Dapivirine is a non-nucleoside inhibitor of reverse transcriptase enzyme with the ability to block the self-replication of HIV, while levonorgestrel is a type of progestin.

Set to be conducted at two clinical sites in the US, the randomised, double-blind trial will be led by IPM's clinical trial partner Microbicide Trials Network (MTN) and funded by the US National Institutes of Health (NIH).

The trial will evaluate the 200mg dapivirine and 320mg levonorgestrel-carrying ring for 14 days in 24 healthy, non-pregnant women aged between 18 to 45.

See Also:

IPM founder and chief executive officer Dr Zeda Rosenberg said: “Women’s sexual and reproductive health needs do not exist in isolation, and neither should their prevention options.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"The only way to end the HIV epidemic is to offer women product options that meet their various needs, and IPM remains committed to making this a reality."

"A long-acting product that gives women two prevention methods in one may be quite appealing.

“The only way to end the HIV epidemic is to offer women product options that meet their various needs, and IPM remains committed to making this a reality.”

The vaginal ring, containing 200mg dapivirine alone, will be used as a placebo for comparison.

The study's primary objective is to evaluate the safety and pharmacokinetics of the ring by measuring levels of the two drugs in blood and vaginal fluid.

With results expected by mid-2018, the trial will also examine product acceptability among the subjects.